US$250m market share
First generic will get atleast 20-30% market share
Gross Profit margin ~55%
Overheads about 2% of revenue (using Teva portfolio metrics) - I use 4%
Simple math gets you a rough EBITDA impact. Can play with numbers to be more conservative.
- Forums
- ASX - By Stock
- MYX
- Ann: FDA approval and first generic launch of Acticlate tablets
MYX
mayne pharma group limited
Add to My Watchlist
1.12%
!
$5.28

Ann: FDA approval and first generic launch of Acticlate tablets, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.28 |
Change
-0.060(1.12%) |
Mkt cap ! $428.9M |
Open | High | Low | Value | Volume |
$5.28 | $5.35 | $5.26 | $385.8K | 72.69K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4 | $5.28 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.35 | 17260 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 5.260 |
2 | 4440 | 5.250 |
1 | 1000 | 5.220 |
1 | 9500 | 5.210 |
2 | 5432 | 5.200 |
Price($) | Vol. | No. |
---|---|---|
5.200 | 20000 | 1 |
5.250 | 20000 | 1 |
5.300 | 21000 | 2 |
5.350 | 17260 | 1 |
5.390 | 20000 | 1 |
Last trade - 16.10pm 14/07/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |